Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2001

View Archived Issues

Licensing opportunity from NIH: novel retroviral vectors for DNA transfer and gene reconstitution

Licensing opportunity from NIH: NSAID-related gene with antitumorigenic properties

Progress reported by Chiron in product pipeline during 2000

Oxigene discusses development progress

Protegrin IB-367 phase I results in ventilator-associated pneumonia reported

MGI Pharma signs letter of intent for exclusive North American license to palonosetron

Two of British Biotech's MMPIs show no advantage over placebo

Roche and deCODE Genetics identify new targets for schizophrenia and PAOD

Combination of PS-519 + thrombolysis may be superior to either therapy alone in embolic stroke

InSite Vision provides product overview

Spin trap agents, with or without tPA, and thromboembolic stroke

Xenerex Biosciences acquires patent to human antibody generation process

Switch Biotech acquires delivery system for skin wounds

Clinically achievable doses of human albumin provide significant neuroprotection in ischemic stroke

ApoA-I Milano shows activity in mouse model of atherosclerotic disease

News from International Stroke Conference: substantial clinical efficacy predicted for NXY-059

Continued progress in product pipeline reported at Interneuron

Intramuscular formulation of Zyprexa clears hurdle on the way to FDA approval

Merck KGaA licenses antidepressant to GlaxoSmithKline

New benzimidazoles useful for atherosclerosis Rx designed at Japanese lab

Takeda claims potent new factor Xa inhibitors

Novel alpha1B-adrenoceptor antagonists from Toray particularly useful in hypertension

New agents for osteoporosis act by inhibiting osteoclast vacuolar ATPase

Antitumor agents derived from UCF-116 result from Kyowa Hakko-Lilly collaboration

Preparation, activity and use of specific IkappaB kinase inhibitors claimed by Aventis

Onconase receives orphan medicinal product designation in Europe

Series of international patents issued to Bayer for new agents for anemia

New oral formulation of Zomig approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...